Innot (Tangshan) Biotechnology Co., Ltd

Innot (Tangshan) Biotechnology Co., Ltd. was established in 2011 and is located in Qian'an High tech Industrial Development Zone, Hebei Province. It is a high-tech enterprise for in vitro diagnostic reagents that integrates research and development, production, and sales. It is a cooperative enterprise between North China University of Technology, an EU CE certified enterprise, and a member of the Hebei Pharmaceutical Industry Association Presidium. It is a typical demonstration enterprise for transformation and upgrading in Hebei Province. The company has a purification workshop of 5000 square meters (one of the largest in the same industry in China), and has five diagnostic reagent production lines, including colloidal gold, enzyme immunoassay, chemiluminescence, nucleic acid testing, and biochips, with an annual production capacity of 20 million people for various diagnostic reagents. The company has obtained 55 product registration certificates, 2 instrument product registration certificates, and 5 invention patents, including Mycoplasma pneumoniae, trachoma virus, and rubella virus. The IgM detection kit for respiratory infection pathogen antibodies (indirect fluorescence method) is the first product in China. The company has a national exclusive respiratory series of products, which can not only detect multiple viruses at the same time, but also achieve whole blood testing and fingertip blood testing. The company's existing employees have a college degree or above, accounting for 80% of the total number of employees. The company has gel electrophoresis image analysis system, filter system, film scriber and other internationally advanced production and testing experimental equipment imported from Germany and the United States. Successfully developed specific antigens and antibodies for various pathogens, including influenza viruses, tuberculosis, and other respiratory and digestive pathogens, for use by multiple well-known domestic enterprises. At the same time, the company has hired experts from research institutions such as the Institute of Microbiology of the Chinese Academy of Sciences, the Academy of Military Medical Sciences, Nankai University, and the China Institute for the Control of Pharmaceutical and Biological Products to form a think tank, providing technical support and consultation for the company's major decisions and product positioning, laying the foundation for the company's development. The company has a 3000 square meter research and development center in Beijing, which is a national high-tech enterprise and a postdoctoral workstation in Zhongguancun. It has 3 Zhongguancun shared laboratories and 7 functional technology platforms. He participated in the project "Research on tuberculosis diagnostic technology and products" in the national "863" special project "Prevention and treatment of major infectious diseases such as AIDS and viral hepatitis". The center has an excellent team composed of doctors, masters and senior professional technicians. The main technicians have many years of experience in research, production and marketing management of diagnostic reagents and molecular biology. At the end of the year and the beginning of the year, after the "COVID-19" broke out nationwide, the novel coronavirus (2019 nCOV) antibody detection kit (colloidal gold method) developed by our company was used for in vitro qualitative detection of novel coronavirus (2019 nCOV) IgM/IgG antibodies in human serum and plasma samples. The test time of this product is short, and the results can be obtained in 15 minutes. It is easy to operate and does not need other instruments. It avoids cross infection and makes outstanding contributions to the prevention and control of COVID-19 epidemic in China and the world. From January 2018 to December 2019, Innot (Tangshan) Biotechnology Co., Ltd. collaborated with LGC, Laboratory of the Government Chemistry (UK Government Chemistry Laboratory) to carry out a joint research and development project of ParaDNA instruments and HyBeacon probe technology in the genetic detection and typing of influenza A virus pathogens, utilizing HyBeacon technology to develop a diagnostic and analytical kit for influenza A virus pathogen typing, Implement testing using the ParaDNA testing platform. Designed based on the seasonal epidemic characteristics of influenza A virus announced by WHO, a single direct sampling operation in an independent response unit can complete the detection and analysis of various influenza A virus subtypes. It is currently the only technical platform capable of on-site detection and can easily be extended to the on-site detection and epidemic monitoring of other infectious pathogens.